Loading the session
Loading the session
Loading instrument
$74.80
+8.45%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:05 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +8.3% (SPY −1.6%, XLV +13.5%). 3 months: −0.3% (SPY −0.4%, XLV +15.5%). 1 year: +1.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PTCT, SPY and XLV · as of 4 Nov 2026
8.3M shares were sold short at the 15 Oct 2026 settlement, 9.9% of the 83.5M shares outstanding; covering them would take 7.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
3 Nov 2026 volume of 2.6M shares was 2.3× the average of the 30 sessions before it (1.1M), as the price rose 11.9%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
The 4 Nov 2026 close of $68.97 was 6.1% above its 50-day average ($65.03) and 2.2% below its 200-day average ($70.56). It has closed below the 200-day for 50 sessions, since 26 Aug 2026. The 50-day average crossed below the 200-day on 18 Sep 2026, 33 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $68.97 on 4 Nov 2026: 24.1% below the 52-week high of $90.87 (9 Jul 2026) and 17.3% above the low of $58.80 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
May 20, 2024
+21.23%October 27, 2023
−22.71%September 15, 2023
−29.77%